How To Order

Getting Started With ADSTILADRIN

ADSTILADRIN IS FULLY AVAILABLE.

Ferring Pharmaceuticals is committed to ensuring a seamless ADSTILADRIN ordering experience

Step 1

Patient identification and submission of Patient Enrollment Form

Submit a completed Patient Enrollment Form: Once a patient has been identified, submit the form by fax to 1-833-322-5233 or online via ferringaccesssupport.com. You will receive a notification via email that your form has been successfully submitted
Ferring Access Support will conduct a benefits investigation.* Upon completion, Ferring Access Support will contact you via phone and/or fax with a benefits investigation summary, which will include details regarding the patient’s coverage:
- Support options may be available for the patient
- Results may include notifying your office of prior authorization requirements

ADSTILADRIN has confirmed 99% coverage for commercial and government-
insured patients¹

Download these helpful resources:

Patient Enrollment Form

Submit your enrollment form at ferringaccesssupport.com

Copay Program Leave Behind

Create an account, register and enroll patients,
and submit claims on hcp.ferringcopay.com

Eligible, commercially insured patients may pay as little as $100^†for each ADSTILADRIN prescription

Step 2

Account setup and ordering ADSTILADRIN

Please validate that your practice location has an active account set up with either Besse Medical or Optum Frontier Therapies
Account setup: If there is not an active account, please set up an account with Besse Medical by phone at 1-800-252-87591-800-252-8759 or by email at advancedtherapies@amerisourcebergen.com or with Optum Frontier Therapies by email at oft_specialtydistribution@optum.com
- Note: Account setup may take 3 to 5 business days provided that all information and documentation submitted are complete
Ordering ADSTILADRIN: Once benefits coverage is confirmed, you can proceed to order
- To order through the specialty distributor, contact Besse Medical at 1-800-252-87591-800-252-8759 or Optum Frontier Therapies at 1-833-754-64571-833-754-6457
- If ordering through the specialty pharmacy, Ferring Access Support will triage your prescription to Optum Frontier Therapies (1-855-768-97271-855-768-9727), and the patient and practice will be contacted by both Optum Frontier Therapies and Ferring Access Support

How to Order
Leave Behind

Flexible payment terms:
Ferring offers 120-day payment terms^‡

Step 3

Instillation of ADSTILADRIN

Schedule the instillation appointment with your patient

Before they leave the office,
book their next
instillation to
keep them consistent on a 90-
day
DOSE ON-TIME schedule
- Schedule a cystoscopy (if the practice requires)
  about 2
  weeks before the next
  instillation^§
Patients may continue quarterly maintenance
treatment as long
as they respond^2,3

Instructions for Use

For assistance, call 1-844-NADOnow1-844-NADONOW (1-844-623-66691-844-623-6669)
Monday to Friday, 9 _AM to 6 _PM ET

Watch video

ADSTILADRIN Ordering Walk-Through

Neal Shore, MD, FACS, a clinician from the ADSTILADRIN clinical trials, provides helpful details about how to order ADSTILADRIN.

*Only commercially insured patients will go through a benefits verification.

^†Available only for patients who meet eligibility requirements. Program does not cover the cost of administration, office visits, or any associated costs. Terms and conditions apply.

^‡Ferring offers approximately 120-day payment terms to its specialty distribution network. Payment terms offered from specialty distributor to healthcare professional may vary.

^§In the phase 3 clinical trial, a cystoscopy was performed within 14 days before the instillation.⁴

NEXT Access

Sign Up to Receive Information and Updates on ADSTILADRIN (nadofaragene firadenovec-vncg)

Your Information

First Name*(Required)

Last Name*(Required)

Specialty*(Required)

Work Email Address*(Required)

NPI Number*(Required)

Practice Name*(Required)

Practice Phone Number

Your Mailing Address

Mailing Address 1*(Required)

Mailing Address 2

City*(Required)

State*(Required)

Zip Code*(Required)

*Required field.

References: 1. Ferring Access Support services for you and your patients. Ferring Pharmaceuticals, Inc. 2025. 2. ADSTILADRIN. Package insert. Ferring Pharmaceuticals, Inc; August 2024. 3. Narayan VM, Boorjian SA, Alemozaffar M, et al. Efficacy of intravesical nadofaragene firadenovec for patients with Bacillus Calmette-Guérin-unresponsive nonmuscle-invasive bladder cancer: 5-year follow-up from a phase 3 trial. J Urol. 2024;212(1):1-12.
4. Data on file. ADSTILADRIN CSR, Ferring Pharmaceuticals, Inc.

Important Safety Information

INDICATION

ADSTILADRIN is a non-replicating adenoviral vector-based gene therapy indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS: ADSTILADRIN is contraindicated in patients with prior hypersensitivity reactions to interferon alfa or to any component of the product.

WARNINGS AND PRECAUTIONS:

Risk with delayed cystectomy: Delaying cystectomy in patients with BCG-unresponsive CIS could lead to development of muscle invasive or metastatic bladder cancer, which can be lethal. If patients with CIS do not have a complete response to treatment after 3 months or if CIS recurs, consider cystectomy.
Risk of disseminated adenovirus infection: Persons who are immunocompromised or immunodeficient may be at risk for disseminated infection from ADSTILADRIN due to low levels of replication-competent adenovirus. Avoid ADSTILADRIN exposure to immunocompromised or immunodeficient individuals.

DOSAGE AND ADMINISTRATION: Administer ADSTILADRIN by intravesical instillation only. ADSTILADRIN is not for intravenous use, topical use, or oral administration.

USE IN SPECIFIC POPULATIONS: Advise females of reproductive potential to use effective contraception during ADSTILADRIN treatment and for 6 months after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during ADSTILADRIN treatment and for 3 months after the last dose.

ADVERSE REACTIONS: The most common (>10%) adverse reactions, including laboratory abnormalities (>15%), were glucose increased, instillation site discharge, triglycerides increased, fatigue, bladder spasm, micturition (urination urgency), creatinine increased, hematuria (blood in urine), phosphate decreased, chills, pyrexia (fever), and dysuria (painful urination).

You are encouraged to report negative side effects of prescription drugs to FDA. Visit www.FDA.gov/medwatch or call 1-800-332-10881-800-332-1088. You may also contact Ferring Pharmaceuticals at 1-888-FERRING1-888-FERRING.

Please see full Prescribing Information for ADSTILADRIN.

How To Order

Getting Started With ADSTILADRIN

Download these helpful resources:

ADSTILADRIN Ordering Walk-Through

Sign Up to Receive Information and Updates on ADSTILADRIN (nadofaragene firadenovec-vncg)

Your Information

Your Mailing Address

Important Safety Information

INDICATION

IMPORTANT SAFETY INFORMATION

Request a Rep

Request a Rep

Your Information

Your Mailing Address

Are you a US healthcare professional?

NEW CLINICAL DATA

NEW CLINICAL
DATA